Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Non-Current Debt (2016 - 2025)

Jaguar Health (JAGX) has disclosed Non-Current Debt for 11 consecutive years, with $7.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Debt fell 64.69% to $7.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.6 million, a 64.69% decrease, with the full-year FY2024 number at $23.5 million, down 24.17% from a year prior.
  • Non-Current Debt was $7.6 million for Q3 2025 at Jaguar Health, down from $10.7 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $31.2 million in Q3 2023 to a low of $7.6 million in Q3 2025.
  • A 5-year average of $21.4 million and a median of $21.8 million in 2024 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: surged 5957.5% in 2021, then tumbled 64.69% in 2025.
  • Jaguar Health's Non-Current Debt stood at $25.0 million in 2021, then decreased by 29.09% to $17.7 million in 2022, then skyrocketed by 74.67% to $31.0 million in 2023, then decreased by 24.17% to $23.5 million in 2024, then crashed by 67.46% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Non-Current Debt are $7.6 million (Q3 2025), $10.7 million (Q2 2025), and $18.4 million (Q1 2025).